Thomas Glocer - Merck Independent Director

<div class='circular--portrait' style='background:#008000;color: #f8f8f8;font-size:3em;padding-top: 38px;;'>MRK</div>
MRK -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

  Director
Mr. Thomas H. Glocer is Independent Director of the Company.Mr. Glocer has extensive management, operational, technology and international business expertise, including his history of accomplishment and executive ability as CEO and a Director of Thomson Reuters Corporationrationration. In addition, his directorships at other public companies, including his service as Lead Director and as a member of the Operations and Technology Committee at Morgan Stanley, provide him with valuable experience on governance issues facing public companies. He is Retired Chief Executive Officer, Thomson Reuters Corporationrationration since December 2011, prior to which he was Chief Executive Officer of Thomson Reuters from 2008 and Chief Executive Officer of its predecessor, Reuters Group PLC, from 2001. Founder and Managing Partner, Angelic Ventures, L.P Director, Council on Foreign Relations nominated Director, Morgan Stanley Member, Board of Trustees, Cleveland Clinic, European Business Leaders Council, Atlantic Council International Advisory Board, Madison Council of the Library of Congress, The Business Council, Advisory Board of the Cambridge Judge Business School, the Columbia College Board of Visitors, and Presidents Council on International Activities at Yale University
Age: 59  Director Since 2007      
908 735-1500  www.merck.com
Glocer was also a director of Merck Sharp & Dohme Corporationrationration from 2007 to 2009, Reuters Group PLC from 2000 to 2008 and Thomson Reuters Corporationrationrationration from 2008 to 2011.

Thomas Glocer Latest Insider Activity

Merck Management Efficiency

Merck Inc has Return on Asset of 0.1273 % which means that on every $100 spent on asset it made $0.1273 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.3938 % implying that it generated $0.3938 on every 100 dollars invested. Merck management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Merck Return on Investment is increasing as compared to previous years. The last year's value of Return on Investment was reported at 22.30. The current Return on Average Assets is estimated to increase to 0.13, while Return on Invested Capital is estimated to decrease to 0.19. Merck Goodwill and Intangible Assets are decreasing as compared to previous years. The last year's value of Goodwill and Intangible Assets was reported at 33.62 Billion. The current Total Assets Per Share is estimated to increase to 37.39, while Asset Turnover is estimated to decrease to 0.55. Merck Total Liabilities is increasing as compared to previous years. The last year's value of Total Liabilities was reported at 58.4 Billion. The current Liabilities Non Current is estimated to increase to about 39 B, while Current Liabilities is estimated to decrease to under 19.2 B.
The company has 27.59 B in debt with debt to equity (D/E) ratio of 99.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. Merck Inc has Current Ratio of 1.19 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Katherine BaickerEli Lilly And
2011
Laurie GlimcherGlaxoSmithKline PLC
2017
Jesse GoodmanGlaxoSmithKline PLC
2017
JeanPhilippe CourtoisAstrazeneca PLC
2008
Ann FudgeNovartis AG
2008
Karen WalkerEli Lilly And
2018
Richard WhitleyGilead Sciences
2008
Daniel PodolskyGlaxoSmithKline PLC
2006
Ronald WilliamsJohnson Johnson
2011
Susan LindquistJohnson Johnson
2004
Roy AndersonGlaxoSmithKline PLC
2007
Mark McClellanJohnson Johnson
2013
Marillyn HewsonJohnson Johnson
2019
Weiying WangAstrazeneca PLC
2019
Kelly KramerGilead Sciences
2016
Philip BroadleyAstrazeneca PLC
2017
Harish ManwaniGilead Sciences
2018
Alicia SecorGW Pharmaceuticals Plc
2017
Thomas LynchGW Pharmaceuticals Plc
2010
Nancy AndrewsNovartis AG
2015
Dimitri AzarNovartis AG
2012

Company Summary

It operates through Pharmaceutical and Animal Health segments. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 71000 people.Merck Company (MRK) is traded on BATS Exchange in USA. It is located in 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States and employs 71,000 people. Merck Company was previously known as Merck Co and was traded on BATS Exchange under the symbol SGP. Merck is listed under Pharmaceutical Products category by Fama And French industry classification.

Merck Inc Leadership Team

Thomas Glocer, Independent Director
Craig Thompson, Independent Director
Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary
Rochelle Lazarus, Independent Director
Christine Seidman, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Wendell Weeks, Independent Director
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Kathy Warden, Independent Director
Paul Rothman, Independent Director
Mary Coe, Independent Director
Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer
Adele Ambrose, Senior Vice President Chief Communications Officer
Joseph Romanelli, IR Contact Officer
Mirian GraddickWeir, Executive Vice President - Human Resources
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Leslie Brun, Lead Independent Director
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Inge Thulin, Independent Director
Pamela Craig, Independent Director
Patricia Russo, Independent Director
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Franklin Clyburn, Executive Vice President Chief Commercial Officer
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Robert Kidder, Independent Director
Thomas Cech, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Clark Golestani, CIO and Executive VP
William Harrison, Lead Independent Director
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Adam Schechter, President of Global Human Health and Executive VP
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
Frank Clyburn, Executive Vice President, Chief Commercial Officer

Stock Performance Indicators

Current Sentiment - MRK

Merck Inc Investor Sentiment

Predominant part of Macroaxis users are now bullish on Merck Company. What is your trading attitude regarding investing in Merck Company? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Portfolio Manager module to state of the art portfolio manager to monitor and improve performance of your invested capital.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page